PUNE, India, April 4, 2018 /PRNewswire/ —
ReportsnReports.com adds the microfluidics market is projected to reach USD 27.91 billion by 2023 from estimated USD 10.06 billion in 2018, at a CAGR of 22.6%. Quick returns on investment coupled with the fast results and improved portability of the medical equipment embedded with microfluidics technology are the factors expected to drive the market during the forecast period. However, complex and time-consuming regulatory approvals process for the microfluidics technology into existing workflow is one of the factors restraining the growth of this market.
[…]
The key players in the global microfluidics market are Danaher (US), Thermo Fisher (US), PerkinElmer (US), Agilent (US), Bio-Rad (US), Becton, Dickinson and Company (US), Roche (Switzerland), Illumina (US), Fluidigm Microfluidics (US), and QIAGEN (Netherlands). Other key players include Dolomite Microfluidics (UK), GYROS PROTEIN TECHNOLOGIES AB (Sweden), Sphere Fluidics (UK), OPKO Health (US), Waters (US), thinXXS Microtechnology (Germany), Abaxis (US), BioMérieux (France), Abbott (US), Dolomite Microfluidics (UK), Microfluidic ChipShop (Germany), Elveflow (France), Cellix (Ireland), Micronit Microtechnologies (Netherlands), MicroLiquid (Spain), MiniFAB (Australia), uFluidix (Canada), Micralyne (US), and Fluigent (France).
Skin diseases like atopic dermatitis and psoriasis have been linked to gut health, yet the…
Red blood cell (RBC) deformability, the ability of RBCs to squeeze through tiny capillaries, is…
Precise diagnosis of infectious diseases is often hindered by a lack of accessible biomarkers that…
Chimeric antigen receptor T-cell (CAR-T) therapy has reshaped the treatment landscape for hematologic cancers, but…
In complex tissue environments, cells constantly interact with dynamic chemical signals, many of which are…
Lewy bodies -intracellular aggregates rich in α‑Synuclein (αSyn)- appear in a stereotyped pattern as Parkinson’s…